[Retinopathy of prematurity - therapy. Part 2]

Area of Science:

• Ophthalmology
• Neonatology
• Vascular Biology

Background:

• Retinopathy of prematurity (ROP) is a serious eye condition affecting premature infants.
• Immature retinal vasculature in premature babies is susceptible to abnormal growth.
• Untreated ROP can lead to significant vision impairment and blindness.

Purpose of the Study:

• To outline updated indications for ROP treatment.
• To review established and emerging therapeutic modalities for ROP.
• To provide guidance on managing ROP in clinical practice.

Main Methods:

• Review of current literature and clinical guidelines for ROP treatment.
• Description of standard treatments: laser photocoagulation and cryotherapy.
• Discussion of the off-label use of intravitreal anti-VEGF injections.

Main Results:

• Revised criteria for initiating ROP treatment are detailed.
• Laser photocoagulation and cryotherapy remain standard interventions.
• Intravitreal anti-VEGF therapy is presented as an alternative, off-label treatment option.

Conclusions:

• Updated indications aim to optimize treatment timing and patient selection for ROP.
• A comprehensive approach incorporating traditional and novel therapies is crucial.
• Further research into the long-term efficacy and safety of intravitreal anti-VEGF in ROP is warranted.